<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00670189</url>
  </required_header>
  <id_info>
    <org_study_id>CA194-002</org_study_id>
    <nct_id>NCT00670189</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer</brief_title>
  <official_title>A Phase 1 Multiple Ascending Dose Study of BMS-833923 in Subjects With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with
      advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Use National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) to establish the maximum tolerated dose, a recommended Phase 2 dose range and schedule, and safety profile of BMS-833923</measure>
    <time_frame>On average a minimum of 60 days up to 3 years</time_frame>
    <description>Use NCI CTCAE to monitor safety assessments including physical findings, laboratory tests, and radiographic assessments to establish the maximum tolerated dose and recommended Phase 2 dose range and schedule of BMS-833923</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of BMS-833923 (XL139) following a single-dose and during daily dosing: Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Study day 1-7, 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of BMS-833923 (XL139) following a single-dose and during daily dosing: Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Study day 1-7, 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of BMS-833923 (XL139) following a single-dose: Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-t)] of BMS-833923 (XL139)</measure>
    <time_frame>Study day 1-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of BMS-833923 (XL139) following a single-dose: Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-833923 (XL139)</measure>
    <time_frame>Study day 1-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of BMS-833923 (XL139) following a single-dose: Plasma half-life (T-HALF) of BMS-833923 (XL139)</measure>
    <time_frame>Study day 1-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of BMS-833923 (XL139) during daily dosing: Minimum observed plasma concentration (Cmin) of BMS-833923 (XL139)</measure>
    <time_frame>Study day 1, 8, 15, 22, 29, 36, 64, and 92</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of BMS-833923 (XL139) during daily dosing: Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-833923 (XL139)</measure>
    <time_frame>Study day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacodynamic effects of BMS-833923 (XL139) on Hedgehog (HH) pathway activation in skin by evaluation of biomarkers such as, but not limited to GLI-1 protein or mRNA expression using immunohistochemistry (IHC) or RT-PCR in a skin biopsies</measure>
    <time_frame>At screening (baseline) and between days 22 and 36 of treatment</time_frame>
    <description>glioma-associated oncogene family of transcription factors (GLI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacodynamic effects of BMS-833923 (XL139) on HH pathway activation in subjects' tumors by evaluation of protein and mRNA of biomarkers such as, but not limited to GLI-1, in pre- and during-treatment tumor samples</measure>
    <time_frame>At screening (baseline) and between days 22 and 36 of treatment. At screening only for NSCLC patients</time_frame>
    <description>glioma-associated oncogene family of transcription factors (GLI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe any preliminary evidence of anti-tumor activity of BMS-833923 (XL139)</measure>
    <time_frame>Every 8 weeks until disease progression</time_frame>
    <description>Tumor assessments by computed tomography (CT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of multiple doses of BMS-833923</measure>
    <time_frame>Adverse event reports: On average a minimum of 60 days up to 3 years</time_frame>
    <description>Medical review of adverse event reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of multiple doses of BMS-833923</measure>
    <time_frame>Conducted at least on days 1, 8, 15, 22 and 36 of the first 36-day cycle and then monthly or biweekly for the first 6 months, then monthly</time_frame>
    <description>The results of vital sign measurements, electrocardiogram (ECGs), pulmonary function tests, multigated radionuclide angiography (MUGA) or echocardiograms, physical examinations, and clinical laboratory tests</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Hedgehog Pathway</condition>
  <condition>Smoothened</condition>
  <condition>Basal Cell Carcinoma (BCC)</condition>
  <condition>Basal Cell Nevoid Syndrome (BCNS)</condition>
  <arm_group>
    <arm_group_label>BMS-833923</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-833923 (XL139)</intervention_name>
    <description>Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit</description>
    <arm_group_label>BMS-833923</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For additional information, please contact the BMS oncology clinical trial information
        service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
        www.BMSStudyConnect.com for more information on clinical trial participation.

        Inclusion Criteria:

          -  Advanced or metastatic cancer (excluding cancer in the blood) or uncontrolled basal
             cell nevoid syndrome or sporadic basal cell carcinoma

          -  Primary or metastatic tumor site accessible for biopsy

          -  Ability to swallow capsules

          -  Subjects with histologically confirmed, advanced stage IIIB or stage IV non-small cell
             lung cancer (NSCLC) with a primary histology of squamous carcinoma who have received
             prior systemic therapy for advanced NSCLC will be enrolled in Part 3

        Exclusion Criteria:

          -  Uncontrolled brain metastasis

          -  Significant cardiovascular disease

          -  Inadequate blood counts

          -  Inadequate liver, kidney or lung function

          -  Gastrointestinal disease within last 3 months

          -  Infection with Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C or
             exposure to attenuated active immunizations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Texas Addiction Research And Tech (Start) Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2008</study_first_posted>
  <last_update_submitted>August 13, 2014</last_update_submitted>
  <last_update_submitted_qc>August 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

